Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriano Chio

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Neurobiology of Aging|December 15, 2022
Whole genome sequencing analysis reveals post-zygotic mutation variability in monozygotic twins discordant for amyotrophic lateral sclerosisGijs H P Tazelaar, Paul J Hop, Meinie Seelen, et al.
EMBO Molecular Medicine|November 9, 2017
G-quadruplex-binding small molecules ameliorate <i>C9orf72</i> FTD/ALS pathology <i>in vitro</i> and <i>in vivo</i>Roberto Simone, Rubika Balendra, Thomas G Moens, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successJeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Nature Communications|January 20, 2023
Integrative genetic analysis illuminates ALS heritability and identifies risk genesSalim Megat, Natalia Mora, Jason Sanogo, et al.
Nature Communications|December 4, 2023
Author Correction: Integrative genetic analysis illuminates ALS heritability and identifies risk genesSalim Megat, Natalia Mora, Jason Sanogo, et al.
The Lancet. Neurology|May 23, 2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichael Benatar, Thomas Hansen, Dror Rom, et al.
Ebiomedicine|October 11, 2025
Optimised machine learning for time-to-event prediction in healthcare applied to timing of gastrostomy in ALS: a multi-centre, retrospective model development and validation studyMarcel Weinreich, Harry McDonough, Mark Heverin, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|October 5, 2017
July 2017 ENCALS statement on edaravoneAmmar Al-Chalabi, Peter M Andersen, Siddharthan Chandran, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 14, 2017
Reconsidering the causality of TIA1 mutations in ALSRick A van der Spek, Wouter van Rheenen, Sara L Pulit, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 5, 2015
The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's diseaseChristina M Lill, Aina Rengmark, Lasse Pihlstrøm, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Neurobiology of Aging|December 15, 2022
Whole genome sequencing analysis reveals post-zygotic mutation variability in monozygotic twins discordant for amyotrophic lateral sclerosisGijs H P Tazelaar, Paul J Hop, Meinie Seelen, et al.
EMBO Molecular Medicine|November 9, 2017
G-quadruplex-binding small molecules ameliorate <i>C9orf72</i> FTD/ALS pathology <i>in vitro</i> and <i>in vivo</i>Roberto Simone, Rubika Balendra, Thomas G Moens, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successJeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Nature Communications|January 20, 2023
Integrative genetic analysis illuminates ALS heritability and identifies risk genesSalim Megat, Natalia Mora, Jason Sanogo, et al.
Nature Communications|December 4, 2023
Author Correction: Integrative genetic analysis illuminates ALS heritability and identifies risk genesSalim Megat, Natalia Mora, Jason Sanogo, et al.
The Lancet. Neurology|May 23, 2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichael Benatar, Thomas Hansen, Dror Rom, et al.
Ebiomedicine|October 11, 2025
Optimised machine learning for time-to-event prediction in healthcare applied to timing of gastrostomy in ALS: a multi-centre, retrospective model development and validation studyMarcel Weinreich, Harry McDonough, Mark Heverin, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|October 5, 2017
July 2017 ENCALS statement on edaravoneAmmar Al-Chalabi, Peter M Andersen, Siddharthan Chandran, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 14, 2017
Reconsidering the causality of TIA1 mutations in ALSRick A van der Spek, Wouter van Rheenen, Sara L Pulit, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 5, 2015
The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's diseaseChristina M Lill, Aina Rengmark, Lasse Pihlstrøm, et al.
Pageof 8